Amgen Inc. (NASDAQ:AMGN) Position Lessened by Donaldson Capital Management LLC

Donaldson Capital Management LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 29.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,057 shares of the medical research company’s stock after selling 4,670 shares during the quarter. Donaldson Capital Management LLC’s holdings in Amgen were worth $3,185,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of AMGN. Flputnam Investment Management Co. raised its position in Amgen by 0.7% during the fourth quarter. Flputnam Investment Management Co. now owns 53,704 shares of the medical research company’s stock valued at $15,468,000 after acquiring an additional 397 shares in the last quarter. Legacy CG LLC raised its holdings in shares of Amgen by 63.2% during the 4th quarter. Legacy CG LLC now owns 22,152 shares of the medical research company’s stock valued at $6,380,000 after purchasing an additional 8,581 shares in the last quarter. Keel Point LLC lifted its stake in shares of Amgen by 5.3% in the 4th quarter. Keel Point LLC now owns 2,123 shares of the medical research company’s stock valued at $611,000 after purchasing an additional 107 shares during the last quarter. Aurora Private Wealth Inc. bought a new stake in Amgen in the fourth quarter worth $247,000. Finally, Bourgeon Capital Management LLC boosted its holdings in Amgen by 54.5% in the fourth quarter. Bourgeon Capital Management LLC now owns 42,258 shares of the medical research company’s stock worth $12,171,000 after purchasing an additional 14,903 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Amgen stock traded down $1.77 during mid-day trading on Monday, hitting $265.51. 1,739,982 shares of the company were exchanged, compared to its average volume of 2,883,643. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The business has a fifty day moving average of $280.76 and a 200 day moving average of $281.55. The company has a market capitalization of $142.29 billion, a PE ratio of 21.40, a price-to-earnings-growth ratio of 2.53 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period last year, the firm posted $4.09 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BMO Capital Markets raised shares of Amgen from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $286.00 to $326.00 in a research report on Tuesday, December 19th. UBS Group cut their price objective on Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research report on Monday, January 29th. Raymond James assumed coverage on Amgen in a report on Thursday, March 28th. They issued a “market perform” rating on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $329.00 price target on shares of Amgen in a report on Wednesday, April 3rd. Finally, Oppenheimer restated an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a research note on Thursday, February 1st. Ten analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $295.30.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.